{"name":"Natco Pharma","slug":"natco","ticker":"NATCOPHARM.NS","exchange":"NSE","domain":"natcopharma.co.in","description":"Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices.","hq":"Hyderabad, India","founded":1989,"employees":"4199","ceo":"Rajeev Nannapaneni","sector":"Oncology Generics / Para IV / API","stockPrice":1112.45,"stockChange":30.05,"stockChangePercent":2.78,"marketCap":"$199.3B","metrics":{"revenue":45625999360,"revenueGrowth":36.3,"grossMargin":82,"rdSpend":0,"netIncome":15571999744,"cash":32042999808,"dividendYield":0.63,"peRatio":12.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Avastin patent cliff ($1.2B at risk)","drug":"Avastin","type":"patent_expiry","sentiment":"negative"},{"date":"2025-06-01","label":"Tarceva patent cliff ($500M at risk)","drug":"Tarceva","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NRC-2694-A","genericName":"NRC-2694-A","slug":"nrc-2694-a","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"NRC-2694-A","genericName":"NRC-2694-A","slug":"nrc-2694-a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-14","type":"regulatory","headline":"Natco Pharma receives US FDA approval for generic version of Avastin","summary":"Natco Pharma has received approval from the US FDA for its generic version of Avastin, a cancer treatment medication.","drugName":"Avastin","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Natco Pharma reports strong Q3 earnings, beats expectations","summary":"Natco Pharma has reported strong Q3 earnings, exceeding market expectations and demonstrating the company's financial stability.","drugName":"","sentiment":"positive"},{"date":"2023-08-22","type":"deal","headline":"Natco Pharma partners with Cipla to expand API business","summary":"Natco Pharma has partnered with Cipla to expand its API business, strengthening its position in the market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxPdHY1dzZ0Y2dwYmh3RWE3d09ROGRmQWhYOFBRVURDOG9idGx1MnMxbzZfOHowMXFSOVZMNUp1cG9aT1YxeFd0UjFXeXpfV3lQdGRiVm5EU2tZUlZiN3JXV1NKd201TGRyb3dFMmw2dHBNWDVoTUZjVy1jV2VkdWJqMm9ld3hZdDJVWkRjdnBxVEVyZjJRNE9VRjJmc2hwbnM4aDFwWjY4TS1sMlpOWk9KTmhCdTBONlRNbjlwWGlLUzN4VkJKQ1Q1TWZweVRMbTZRUEJESGpxNVl2MnFoNkE?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry - Whalesbook","headline":"India's Drugmakers Rush Generic Semaglutide After Patent Expiry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxOWHRwTGxhaHZJbk5OQjViVUQ3ZmkwRjdMalNDT1AzOHpSOGdEb29hY21GSmlhWXhrdFFUMFJhOTJzR0Y0RDlkbzduVjZiQVZ4Sy1yODVfTjdQRVctazYtRmg1NmhjWUVCamt2QVhZNk1Wa25hVUFzNHdxVjQ5cUNfcEp4bDVDWDNySkdKZ3g4a0ZSTHVLX2NZLUtFNEY5aVB5WWVGY28wQnZMR1RsV0FUX2NBcXBQWVR1ZWc5enNzOS11M2NHczc1Xzg3NWdEQUl1d3R0UHVGWlVyZTlBUVJ3?oc=5","date":"2026-03-20","type":"regulatory","source":"Whalesbook","summary":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance - Whalesbook","headline":"Semaglutide Patent Expiry: India mein Generic Drugs ka Toofan! Prices **70%** tak girne ka chance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNeEppOWZPOGZfYnl3d3JUOEN5UURpNnZieE9idThnYVA3X3p3V3pFQ1pyS3QzVXZUY3UtR05QLWxJUWJOcU81X0pNWGNldFI4c296andCUS1PNWRsUWxzLU53eFNUQ3V3VGZ3MlFyYmw5WkhJRGJHSGVoXzF2M1NJLWhfT0xIN0pxd1d6aHNqaGJoSkdCTzZ2MlRaT1hBVWJsdXUwM1NIZTR4dkcteDd5enhhMVJUd195OUJwXw?oc=5","date":"2025-12-08","type":"earnings","source":"TechStock²","summary":"Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook - TechStock²","headline":"Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPZWFWd09BZjA4T2VkVExkMjF6cmpqbjVNbUhGN3hERW84bG9KQVRCRnQxWEdPOU9GalZOOUZncTFCOE81UV9tYU56X2ZoVzU1c0xQN08zNkU2TjhYNm85UExCQWdBNFAxbVNrWUF4QUUyUWpzS3JKcHM5NEVTcmc1alZGTnBQMWdxNVBPNkl2QTNUR0xxVF9LcnFrNA?oc=5","date":"2025-12-02","type":"pipeline","source":"Meyka","summary":"Natco Pharma Shares: Bullish Trends Ahead as AI Signals More Growth - Meyka","headline":"Natco Pharma Shares: Bullish Trends Ahead as AI Signals More Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxNaVloVjNXNXc1cllEdHpWRWhXbWFydUppbFc5Ums1QXNuWUlmS2FlUGxhUDdzSms2ekx2UThpRGNMUUxGRjg0dFo5N2Z4S1FfWXB2QTE2azdveDUxdHhyQ3BsVjBkUU93cmR0alpfV0RyRGZvUGk4YW9xemlCQzhzR1d2cUNCdzEwaGs5dEZXVUY5SC1iVXlKUmxvcjY3c0JHNTdCbEpwZFV6MEVudEtRYWowR0pmell4X1FrTHZxT1R6TkhDd2xGU0l0MWIyVldxYmxXTkpyNA?oc=5","date":"2025-12-02","type":"regulatory","source":"TechStock²","summary":"Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast - TechStock²","headline":"Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Fore","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE8xcjJvOExfcGkwNUZjQ01ZVmpIc1RwQ1FjYWRmNEJYd1hEdDdRa2xRcXJxdGtvdFNGa0ltS3hlZ2g5Q1gtRHhUeFFUZ0JzNlBnZ0l2OA?oc=5","date":"2023-06-22","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Tamilnad Mercantile Bank Limited (TMB.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Tamilnad Mercantile Bank Limited (TMB.NS) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5UbFlSTVU4d0ViZVVIOE5uT2NVdWxTUVc5TVdrS19HRk9LaExTZUJ2RG1KbDQxLTZETlQydUlfR2s0SnBNM2tQckpNMGEyeEphRHo2LXJGWV8yeE1tN2c?oc=5","date":"2017-08-08","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Ajanta Pharma Limited (AJANTPHARM.NS) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Ajanta Pharma Limited (AJANTPHARM.NS) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBwc3B5NlRrZFJpRHRHeVJKbDZqUlA3QXN0X2p5QXluMW1YRlhkdWdULVU5S3ltOTh3SDhZTERKM1lEbXdxS1ROaThoVTY0cXgyWXBsejVqcGFWc19wZ0Vvb3A4UGY?oc=5","date":"2017-07-30","type":"pipeline","source":"Yahoo Finance Singapore","summary":"NATCO Pharma Limited (NATCOPHARM.BO) latest stock news and headlines - Yahoo Finance Singapore","headline":"NATCO Pharma Limited (NATCOPHARM.BO) latest stock news and headlines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFA1R0FpMWtiU2dKZjk1SW9UVURoazh0cnR5WUp2bWk4NFBTVUNxTkd3Qmp6ZFBvSU1pWU4xaWlFTVQzT05zSUpwd25iemFqSDJpTGxJY1dEaEF2REo4U3I3Z3hieW56Tmx4?oc=5","date":"2017-07-17","type":"pipeline","source":"Yahoo Finance Singapore","summary":"NATCO Pharma Limited (NATCOPHARM.NS) company profile and facts - Yahoo Finance Singapore","headline":"NATCO Pharma Limited (NATCOPHARM.NS) company profile and facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE5WaFE1b1VXbThOZUVsM2ZDN1dtZ0lLSk9sTGV4eE1McnhzOGpYQ3NzUjZrUXdzZWtCQ0dRdUwyMEZ5T1BKanI2SFJmMC1iMzBwLUg4Smg4OA?oc=5","date":"2017-05-31","type":"pipeline","source":"Yahoo Finance Australia","summary":"Cipla Limited (CIPLA.NS) stock price, news, quote and history - Yahoo Finance Australia","headline":"Cipla Limited (CIPLA.NS) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Tarceva","drugSlug":"erlotinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2025-06-01","territory":"US","annualRevenue":500000000},{"drugName":"Avastin","drugSlug":"bevacizumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Sun Pharma","Cipla","Dr. Reddy's Laboratories"],"therapeuticFocus":["Oncology","API"],"financials":null,"yahoo":{"currentPrice":1112.45,"previousClose":1082.4,"fiftyTwoWeekHigh":1124,"fiftyTwoWeekLow":741.05,"fiftyTwoWeekRange":"741.05 - 1124.0","fiftyDayAverage":923.23,"twoHundredDayAverage":893.52,"beta":0.19,"enterpriseValue":164442046464,"forwardPE":28.3,"priceToBook":2.3,"priceToSales":4.37,"enterpriseToRevenue":3.6,"enterpriseToEbitda":9.22,"pegRatio":0,"ebitda":17844000768,"ebitdaMargin":39.1,"freeCashflow":0,"operatingCashflow":0,"totalDebt":2607000064,"debtToEquity":3,"currentRatio":0,"returnOnAssets":0,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":11,"targetMeanPrice":987.36,"targetHighPrice":1480,"targetLowPrice":712,"dividendRate":6.5,"payoutRatio":0.06,"fiveYearAvgDividendYield":0.78,"exDividendDate":1771372800,"insiderHeldPercent":51,"institutionHeldPercent":12.6,"sharesOutstanding":179109870,"floatShares":83436028,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":86.92,"epsForward":39.3,"revenuePerShare":254.75,"bookValue":482.88,"officers":[{"age":80,"name":"Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS.","title":"MD & Chairman"},{"age":48,"name":"Mr. Rajeev  Nannapaneni","title":"CEO & Vice Chairman"},{"age":73,"name":"Dr. Donthineni Linga Rao M.D.","title":"President of Technical Affairs & Whole Time Director"},{"age":null,"name":"Mr. Chekuri Venkat Ramesh C.S.","title":"Company Secretary & Compliance Officer"},{"age":67,"name":"Mr. Potluri Sivaramakrishna Prasad","title":"Executive VP of Corporate Engineering Services & Whole Time Director"},{"age":null,"name":"Mr. Amit  Parekh","title":"CFO, Executive VP of Finance & Accounts"},{"age":null,"name":"Nadella Malleswara Rao","title":"VP & Head of Operations"},{"age":null,"name":"N. Sadasiva Rao","title":"Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.natcopharma.co.in","phone":"91 40 2354 7532"}}